Prospective Grant of Exclusive License: The Development of Thalidomide Analogs for the Treatment of Cancer, 23735-23736 [E9-11680]

Download as PDF Federal Register / Vol. 74, No. 96 / Wednesday, May 20, 2009 / Notices Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Rm 5152, MSC 7844, Bethesda, MD 20892. (301) 435–1159. rubinsteinal@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel, NCF Competitive Revisions. Date: June 5, 2009. Time: 1 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: The Fairmont Washington, DC, 2401 M Street, NW., Washington, DC 20037. Contact Person: Lawrence Baizer, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4152, MSC 7850, Bethesda, MD 20892. (301) 435– 1257. baizer@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel, BPNS Competitive Revisions. Date: June 5, 2009. Time: 2 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: The Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102. Contact Person: Geoffrey G. Schofield, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4040–A, MSC 7850, Bethesda, MD 20892. (301) 435– 1235. geoffreys@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel, Biomedical Informatics. Date: June 5, 2009. Time: 2 p.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852. Contact Person: Bill Bunnag, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3156, MSC 7770, Bethesda, MD 20892. (301) 435– 1177. bunnagb@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel, APDA: Review of Competing Revisions. Date: June 5, 2009. Time: 3 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: The Allerton Hotel Chicago, 701 North Michigan Avenue, Chicago, IL 60611. Contact Person: Estina E. Thompson, PhD, MPH, Scientific Review Officer, Center for VerDate Nov<24>2008 15:27 May 19, 2009 Jkt 217001 Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3178, MSC 7848, Bethesda, MD 20892. (301) 496– 5749. thompsone@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel, Collaborative Applications in Adult Psychopathology and Disorders of Aging. Date: June 5, 2009. Time: 12 p.m. to 3 p.m. Agenda: To review and evaluate grant applications. Place: The Allerton Hotel Chicago, 701 North Michigan Avenue, Chicago, IL 60611. Contact Person: Estina E. Thompson, PhD, MPH, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3178, MSC 7848, Bethesda, MD 20892. (301) 496– 5749. thompsone@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel, CMBG ARRA Competing Revisions. Date: June 5, 2009. Time: 12 p.m. to 1 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Toby Behar, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4136, MSC 7850, Bethesda, MD 20892. (301) 435– 4433. behart@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel, Psychosocial Risk Prevention: ARRA Renewal Applications. Date: June 5, 2009. Time: 12 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Avenue Hotel Chicago, 160 Huron Street, Chicago, IL 60611. Contact Person: Anna L. Riley, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3114, MSC 7759, Bethesda, MD 20892. (301) 435– 2889. rileyann@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 23735 Dated: May 11, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–11580 Filed 5–19–09; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: The Development of Thalidomide Analogs for the Treatment of Cancer AGENCY: National Institutes of Health, Public Health Service, HHS. ACTION: Notice. SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in US Patent Application 60/ 792,098 entitled ‘‘Tetrahalogenated Compounds Useful as Inhibitors’’ [HHS Ref. E–080–2006/0–US–01], PCT Application PCT/US2007/008849 entitled ‘‘Tetrahalogenated Compounds Useful as Inhibitors’’ [HHS Ref. E–080– 2006/0–PCT–02], Australian Patent Application 2007238785 entitled ‘‘A New Series Of Thalidomide Analogs That Have Potent Anti-angiogenic Properties’’ [HHS Ref. E–080–2006/0– AU–03], Canadian Patent Application 2,648,216 entitled ‘‘A New Series Of Thalidomide Analogs That Have Potent Anti-angiogenic Properties’’ [HHS Ref. E–080–2006/0–CA–04], European Patent Application 07755201.6 entitled ‘‘A New Series Of Thalidomide Analogs That Have Potent Anti-angiogenic Properties’’ [HHS Ref. E–080–2006/0– EP–05], US Patent Application 12/ 287,597 entitled ‘‘A New Series Of Thalidomide Analogs That Have Potent Anti-angiogenic Properties’’ [HHS Ref. E–080–2006/0–US–06], and all continuing patents, patent applications, and foreign counterparts thereto, to CuriRx, Inc., which has offices in Andover, Massachusetts. The patent rights in these inventions have been assigned to and/or exclusively licensed to the Government of the United States of America. The prospective exclusive license territory may be worldwide, and the field of use may be limited to: The use of Gu998 (Compound 19e), Gu973 (Compound 19f), Gu1029 (Compound 20d) or Gu992 (Compound 20g) as cancer therapeutics. E:\FR\FM\20MYN1.SGM 20MYN1 23736 Federal Register / Vol. 74, No. 96 / Wednesday, May 20, 2009 / Notices DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 20, 2009 will be considered. Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: David A. Lambertson, Ph.D., Senior Licensing and Patenting Manager, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435–4632; Facsimile: (301) 402– 0220; e-mail: lambertsond@od.nih.gov. ADDRESSES: The invention concerns the use of tetrahalogenated thalidomide derivatives for the treatment of cancer. Thalidomide has been shown to be a potent inhibitor of angiogenesis (the formation of new blood vessels). The popular belief is that angiogenesis enhances tumor formation by providing tumors with increased nutrients, allowing their sustained growth. However, thalidomide is a natural teratogen that can cause severe birth defects, and has a propensity towards causing neotropenia and deep venous thrombosis in recipients of the drug. This led researchers to seek out safer derivatives of thalidomide that retain an anti-cancer activity. The tetrahalogenated derivatives disclosed by this technology may represent both a safer alternative to thalidomide and potentially a more successful alternative to the angiogenesis inhibitors currently being clinically tested. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. SUPPLEMENTARY INFORMATION: VerDate Nov<24>2008 15:27 May 19, 2009 Jkt 217001 Dated: May 12, 2009. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E9–11680 Filed 5–19–09; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: The Manufacture, Use, Distribution of and Sale of Fused Azepinone Cyclin Dependent Kinase Inhibitors as Therapeutics AGENCY: National Institutes of Health, Public Health Service, HHS. ACTION: Notice. SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Patent No. 6,610,684 entitled, ‘‘Fused Azepinone Cyclin Dependent Kinase Inhibitors’’ and all foreign counterparts [HHS Ref. No. E–025–1998/0] to ShanaRx Pharmaceuticals. The patent rights in this invention have been assigned to the United States of America. The prospective exclusive license territory may be worldwide and the field of use may be limited to the use of the Cyclin Dependent Kinase Inhibitors and their methods of use in the Licensed Patent Rights for the treatment of: (i) Disorders caused by damage, injury, infection in or abnormal function of the peripheral or central nervous system including pain, neuropathy, retinal degeneration, glaucoma, Alzheimer’s disease, Parkinson’s disease, ALS, depression, schizophrenia, and anxiety; (ii) disorders caused by damage, injury, infection in or abnormal function of cerebral vasculature and cardiac vasculature including cardiac failure and myocardial infections; (iii) cancer and neoplastic disorders; (iv) inflammatory and autoimmune diseases including Multiple Sclerosis; and (v) endocrine and neuroendocrine disorders including Diabetes Mellitus. DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before August 18, 2009 will be considered. PO 00000 Frm 00057 Fmt 4703 Sfmt 4703 ADDRESSES: Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated co-exclusive license should be directed to: Whitney A. Hastings, M.S., Licensing and Patenting Manager, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804. Telephone: (301) 451–7337; Facsimile: (301) 402– 0220; E-mail: hastingw@mail.nih.gov. The invention describes a class of cyclin dependent kinase (CDK) inhibitors that have anti-proliferative activity in human tumor cell lines. CDKs are important in the control of the cell cycle and alterations in CDK expression, function, or regulation are associated with diseases characterized by cellular proliferation. Increasing CDK activity has been reported in many cancers and observed in a wide variety of primary human tumors and human tumorderived cell lines, including lung, breast, brain, bone, skin, bladder, kidney, ovary, liver, colon, pancreas as well as in leukemia. The compounds of this invention have also been found to potently inhibit GSK3beta activity. Some of compounds of this invention have been shown to be more potent towards the GSK3beta target than towards CDKs. The GSK3beta enzyme, a proline-directed serine-threonine kinase, has been linked to a variety of cellular processes and several disparate areas of biology. Thus, this technology could provide therapeutic opportunities for a variety of indications, including Alzheimer’s, neurological disorders, and cardiac failure. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within ninety (90) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. SUPPLEMENTARY INFORMATION: E:\FR\FM\20MYN1.SGM 20MYN1

Agencies

[Federal Register Volume 74, Number 96 (Wednesday, May 20, 2009)]
[Notices]
[Pages 23735-23736]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-11680]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: The Development of 
Thalidomide Analogs for the Treatment of Cancer

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR part 404.7(a)(1)(i), that the National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
an exclusive patent license to practice the inventions embodied in US 
Patent Application 60/792,098 entitled ``Tetrahalogenated Compounds 
Useful as Inhibitors'' [HHS Ref. E-080-2006/0-US-01], PCT Application 
PCT/US2007/008849 entitled ``Tetrahalogenated Compounds Useful as 
Inhibitors'' [HHS Ref. E-080-2006/0-PCT-02], Australian Patent 
Application 2007238785 entitled ``A New Series Of Thalidomide Analogs 
That Have Potent Anti-angiogenic Properties'' [HHS Ref. E-080-2006/0-
AU-03], Canadian Patent Application 2,648,216 entitled ``A New Series 
Of Thalidomide Analogs That Have Potent Anti-angiogenic Properties'' 
[HHS Ref. E-080-2006/0-CA-04], European Patent Application 07755201.6 
entitled ``A New Series Of Thalidomide Analogs That Have Potent Anti-
angiogenic Properties'' [HHS Ref. E-080-2006/0-EP-05], US Patent 
Application 12/287,597 entitled ``A New Series Of Thalidomide Analogs 
That Have Potent Anti-angiogenic Properties'' [HHS Ref. E-080-2006/0-
US-06], and all continuing patents, patent applications, and foreign 
counterparts thereto, to CuriRx, Inc., which has offices in Andover, 
Massachusetts. The patent rights in these inventions have been assigned 
to and/or exclusively licensed to the Government of the United States 
of America.
    The prospective exclusive license territory may be worldwide, and 
the field of use may be limited to:

    The use of Gu998 (Compound 19e), Gu973 (Compound 19f), Gu1029 
(Compound 20d) or Gu992 (Compound 20g) as cancer therapeutics.


[[Page 23736]]



DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before July 
20, 2009 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: David A. Lambertson, Ph.D., Senior 
Licensing and Patenting Manager, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, MD 20852-3804; Telephone: (301) 435-4632; Facsimile: (301) 
402-0220; e-mail: lambertsond@od.nih.gov.

SUPPLEMENTARY INFORMATION: The invention concerns the use of 
tetrahalogenated thalidomide derivatives for the treatment of cancer. 
Thalidomide has been shown to be a potent inhibitor of angiogenesis 
(the formation of new blood vessels). The popular belief is that 
angiogenesis enhances tumor formation by providing tumors with 
increased nutrients, allowing their sustained growth. However, 
thalidomide is a natural teratogen that can cause severe birth defects, 
and has a propensity towards causing neotropenia and deep venous 
thrombosis in recipients of the drug. This led researchers to seek out 
safer derivatives of thalidomide that retain an anti-cancer activity. 
The tetrahalogenated derivatives disclosed by this technology may 
represent both a safer alternative to thalidomide and potentially a 
more successful alternative to the angiogenesis inhibitors currently 
being clinically tested.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, the NIH receives 
written evidence and argument that establishes that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: May 12, 2009.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E9-11680 Filed 5-19-09; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.